Clicky

Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)

Description: Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.


Keywords: Medicine Biotechnology Cancer Immunology Treatment Of Cancer Rheumatoid Arthritis Arthritis Psoriasis Inflammatory Diseases Glaucoma Carcinoma Hepatocellular Carcinoma Immunosuppressants Uveitis Treatment Of Psoriasis Treatment Of Inflammatory Diseases Biotie Therapies Treatment Of Inflammatory Disease Autoimmune Inflammatory Diseases Immune Inflammatory Diseases

Home Page: www.canfite.com

CANF Technical Analysis

10 Bareket Street
Petah Tikva, 4951778
Israel
Phone: 972 3 924 1114


Officers

Name Title
Dr. Pnina Fishman Ph.D. Scientific Founder, CEO & Director
Mr. Motti Farbstein Chief Operating & Financial Officer
Dr. Sari Fishman Ph.D. VP of Bus. Devel.
Dr. Ilan Cohn Ph.D. Co-Founder & Chairman
Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D. Sr. Clinical Advisor

Exchange: NYSE MKT

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.7089
Price-to-Sales TTM: 25.8032
IPO Date: 2012-11-06
Fiscal Year End: December
Full Time Employees: 8
Back to stocks